The CSL Limited (ASX: CSL) share price climbed 3.3% to print a record high of $269.93 today after leading research house UBS reportedly upgraded its '12 month price target' on the stock to a heady $295.
Over the last 6 months a number of high profile brokers have also returned bullish verdicts on the blood products business mainly thanks to the belief that the pricing environment for its core blood products is improving.
Back in August a research note out of Goldman Sachs noted how blood or immunoglobulin products represented around 60% of sales for CSL, with Goldman noting the blood products business remains "the foundation of its positive stance on the business."
Other influential brokers have also tipped CSL to enjoy a strong couple of years as it reaps the benefits of prior investments to ramp up blood products supply, while competitors fails to keep up.
